In letter to the editor "Comment on: Statin use and risk of diabetes mellitus" authors found the statement "pravastatin 40 mg/d reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study" erroneous. As per our opinion the statement is right but had been referenced incorrectly. 
Core tip: The statement "Pravastatin has shown to decrease the risk of developing diabetes by 30%" is correct and had been wrongly referenced in "Statin use and risk of diabetes mellitus" by Chogtu et al . 
TO THE EDITOR
We thank Eren et al for showing interest in the review article "statin use and risk of diabetes mellitus" [1] . Eren et al [2] have pointed to an apparent factual error in the following statement: "pravastatin 40 mg/d reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study (WOSCOPS)". However, in our opinion, this statement is correct if we refer to WOSCOPS 2001, in which authors have put forth that pravastatin in a dose of 40 mg/d resulted in a 30% reduction (P = 0.042) in the risk of diabetes [3] . Haffner [4] in an editorial in the same issue of Circulation has also alluded to the fact that Pravastatin reduced incidence of diabetes by 30% -though with a caveat that these results should be cautiously interpreted as the statistical significance in WOSCOPS 2001 was modest. [3] rather than Kotseva et al [5] . We again thank Eren et al [2] to bring this error to our notice.
